Author details

Full Name

Andrea Wittmann

Affiliation

ORCID

Career Start Year

2007

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36786841	Correction to: Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-isÂ a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.	Acta Neuropathol	2023
36437415	Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-isÂ a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification.	Acta Neuropathol	2023
37075810	LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.	Neuro Oncol	2023
34417833	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum.	Acta Neuropathol	2021
33585982	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).	Acta Neuropathol	2021
34545083	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B.	Nat Commun	2021
31867747	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) - a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14.	Neuropathol Appl Neurobiol	2020
31768671	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations.	Acta Neuropathol	2020
29766299	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.	Acta Neuropathol	2018
30143858	Methylome analysis and whole-exome sequencing reveal that brain tumors associated with encephalocraniocutaneous lipomatosis are midline pilocytic astrocytomas.	Acta Neuropathol	2018
27556362	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.	Oncotarget	2016
26923874	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.	Cancer Cell	2016
25965575	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.	Cancer Cell	2015
24651015	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.	Cancer Cell	2014
25043047	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma.	Nature	2014
22160402	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.	Acta Neuropathol	2012
22832583	Dissecting the genomic complexity underlying medulloblastoma.	Nature	2012
21911727	FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.	J Clin Oncol	2011
21632505	Adult medulloblastoma comprises three major molecular variants.	J Clin Oncol	2011
21840481	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.	Cancer Cell	2011
20516456	Molecular staging of intracranial ependymoma in children and adults.	J Clin Oncol	2010
21060032	TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.	J Clin Oncol	2010
20479417	Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.	J Clin Oncol	2010
19378321	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome.	Genes Chromosomes Cancer	2009
19406988	High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.	Blood	2009
19255330	Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.	J Clin Oncol	2009
18398503	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.	J Clin Invest	2008
17344319	Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma.	Nucleic Acids Res	2007
17592618	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas.	Genes Chromosomes Cancer	2007